13F-HR filed by Davern Capital Partners, LP
Davern Capital Partners, LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-13, with 14 holding rows worth $309,295,331.
- Accession
- 0000905148-26-000704
- Filer
- CIK 2003147
- Filed
- 2026-02-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 14 entries on the cover page, a total value of $309,295,331 stated on the cover page (in dollars after the unit check, H1), rows summing to $309,295,331 with VALUE read as dollars as filed, 13F file number 028-26332. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Pfizer Inc. | 717081103 | COM | 2,042,242 | $50,851,826 | dollars as filed | |
| REGENERON PHARMACEUTICALS COM | 75886F107 | Stock | 52,420 | $40,461,425 | dollars as filed | |
| BIONTECH SE SPONSORED ADS | 09075V102 | ADR | 371,216 | $35,339,763 | dollars as filed | |
| ROYALTY PHARMA PLC | G7709Q104 | SHS CLASS A | 840,650 | $32,482,716 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 35,685 | $30,009,301 | dollars as filed | |
| LEGEND BIOTECH CORP | 52490G102 | SPONSORED ADS | 1,056,668 | $22,971,962 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 1,028,298 | $22,314,067 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 238,477 | $18,865,915 | dollars as filed | |
| NATERA INC COM | 632307104 | Stock | 78,650 | $18,017,929 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 8,307 | $8,927,367 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 261,615 | $8,141,459 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 210,648 | $7,644,416 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 162,005 | $6,726,448 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 48,502 | $6,540,737 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000905148-26-000704 | this filing | 2026-02-13 | acceptance time not in the bulk data set |